DIAGNOS Upsizes Private Placement to $3.65 Million
DIAGNOS Inc. (“DIAGNOS” or the “Company”) (TSXV: ADK and OTCQB: DGNOF) recently announced an exciting development regarding its brokered private placement. Driven by considerable demand from investors, the company has opted to increase the size of its previously announced placement to a total of approximately $3.65 million. This adjustment signifies DIAGNOS's commitment to leverage the financial support for its core health technology initiatives.
Details of the Offering
This amended offering will involve issuing up to 12,166,667 units at an issue price of $0.30 per unit. Each unit includes one common share and one common share purchase warrant which can be exercised at a price of $0.40 per share. Importantly, investors will have the opportunity to benefit from this warrant for a period of eighteen months following the closing date.
Strong Investor Interest
The increase in the offering size is a clear reflection of the positive reception from investors eager to support DIAGNOS's vision. The offering will be led by Centurion One Capital Corp., the dedicated lead agent working closely with DIAGNOS to facilitate this funding round.
Allocation of Funds
Proceeds from this offering will be strategically allocated toward regulatory affairs, product development, and business expansion initiatives. By securing this funding, DIAGNOS aims to enhance its operational capabilities and further its commitment to early disease detection utilizing advanced AI technology
Target Regions for the Offering
The institutions offering these units will operate under private placement exemptions across various provinces in Canada, as well as certain jurisdictions outside Canada as agreed upon. This strategic approach allows DIAGNOS to adhere to compliance regarding the issuance of its securities.
Projected Closing Date
The company anticipates that the offering will close around the beginning of December, contingent upon meeting regulatory approvals, including those required by the TSX Venture Exchange.
Involvement of Insiders
Notably, some of the company’s insiders and representatives from the lead agent may participate in acquiring units during this offering, which is expected to account for nearly 50% of the total offering. Such transactions will adhere to regulations designed to protect minority shareholders.
About DIAGNOS Inc.
DIAGNOS is a public Canadian corporation focusing on the early detection of critical eye-related health issues. By harnessing the power of artificial intelligence, DIAGNOS is revolutionizing how healthcare clinicians operate. Their innovative solutions aim to enhance diagnostic accuracy and improve patient outcomes globally, bridging the gap between technology and healthcare.
Commitment to Innovation
As DIAGNOS moves forward, it remains dedicated to refining its artificial intelligence applications, promising a brighter future in healthcare diagnostics. Collaborations with visionary partners are essential for their mission, ensuring the tools developed will continue to evolve and meet the challenging demands of tomorrow’s health landscape.
About Centurion One Capital Corp.
Centurion One Capital Corp. stands out in the investment sector with its unique approach. By investing in visionary entrepreneurs, they aim to address the biggest challenges ahead. Their ethos revolves around building meaningful partnerships within ecosystems that encourage growth and innovation.
Frequently Asked Questions
What is the total amount being raised by DIAGNOS in this offering?
DIAGNOS is raising up to approximately $3.65 million through its brokered private placement.
What will the proceeds of the offering be used for?
The funds raised will primarily support regulatory affairs, product development, and overall business development.
Who is leading the brokered private placement?
The offering is being led by Centurion One Capital Corp. as the lead agent.
When is the expected closing date for the offering?
The offering is projected to close around early December 2025, subject to regulatory approval.
What is the mission of DIAGNOS Inc.?
DIAGNOS focuses on early detection of critical eye-related health problems utilizing artificial intelligence to enhance healthcare outcomes.
